Can Doctors Predict Which Rheumatoid Arthritis Patients Will Respond to Treatment?
https://pixabay.com/en/skeleton-hand-bones-anatomy-joint-778069/

Can Doctors Predict Which Rheumatoid Arthritis Patients Will Respond to Treatment?

Not all treatments work for every patient, with rheumatoid arthritis (RA) medications being the perfect example. Disease-modifying anti-rheumatic drugs (DMARDs) are the standard of care for RA despite the fact…

Continue Reading Can Doctors Predict Which Rheumatoid Arthritis Patients Will Respond to Treatment?
This New Collaboration Aims to Create Gene Therapies for Duchenne Muscular Dystrophy
rawpixel / Pixabay

This New Collaboration Aims to Create Gene Therapies for Duchenne Muscular Dystrophy

According to CureDuchenne, two companies have began a collaboration in an effort to create new gene therapies for Duchenne muscular dystrophy (DMD). Ultragenyx and Solid Bioscience are both using their…

Continue Reading This New Collaboration Aims to Create Gene Therapies for Duchenne Muscular Dystrophy
Researchers Provide a Better Understanding of sJIA and Still’s Disease
Sourced from publicdomainpictures.net (https://www.publicdomainpictures.net/en/view-image.php?image=275669&picture=chemical-research)

Researchers Provide a Better Understanding of sJIA and Still’s Disease

According to Healio, medical professionals from Boston Children's Hospital have conducted research that provides a better look at systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease. They looked specifically…

Continue Reading Researchers Provide a Better Understanding of sJIA and Still’s Disease
First Patient Dosed in Trial of Hypoparathyroidism Treatment, AZP-3601
DarkoStojanovic / Pixabay

First Patient Dosed in Trial of Hypoparathyroidism Treatment, AZP-3601

Amolyt Pharma has recently announced that they have dosed the first patient in their trial of AZP-3601, a treatment for hypoparathyroidism. According to GlobeNewswire, this treatment will adequately address the…

Continue Reading First Patient Dosed in Trial of Hypoparathyroidism Treatment, AZP-3601
Mouse Study Reveals Possible Therapy for Charcot-Marie-Tooth Disease
source: pixabay.com

Mouse Study Reveals Possible Therapy for Charcot-Marie-Tooth Disease

Researchers have recently conducted a study using mouse models of Charcot-Marie-Tooth (CMT) disease, titled "CMTM6 Expressed on the Adaxonal Scwann Cells Surface Restricts Axonal Diameters in Peripheral Nerves." It was…

Continue Reading Mouse Study Reveals Possible Therapy for Charcot-Marie-Tooth Disease
Dystrophic Epidermolysis Bullosa Treatment Receives Fast Track Designation
source: pixabay.com

Dystrophic Epidermolysis Bullosa Treatment Receives Fast Track Designation

The FDA has recently granted the Fast Track designation to AGLE-102, a treatment for dystrophic epidermolysis bullosa. This designation will allow for the treatment to reach patients at a quicker…

Continue Reading Dystrophic Epidermolysis Bullosa Treatment Receives Fast Track Designation
FDA Grants Breakthrough Therapy Designation for Chronic Kidney Disease Treatment
stevepb / Pixabay

FDA Grants Breakthrough Therapy Designation for Chronic Kidney Disease Treatment

The FDA has recently granted the Breakthrough Therapy designation to FARXIGA, a chronic kidney disease treatment created by AstraZeneca. This designation will allow for a quicker development, which will hopefully…

Continue Reading FDA Grants Breakthrough Therapy Designation for Chronic Kidney Disease Treatment